Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
218 words
A treatment method for regulating the menstrual cycle of a presenting patient, the menstrual cycle having a first occurring follicular phase followed by a luteal phase, and the patient having a presenting endogenous estrogen characteristic, comprising: (A) determining the presenting endogenous estrogen characteristic of the patient and identifying the patient's presenting endogenous estrogen characteristic as one of (1) euestrogenic, (2) hyperestrogenic, (3) hypoestrogenic; (B) administering to the patient effective dosages of pharmacologically active steroid compositions in an ordered temporal succession based on the identified endogenous estrogen characteristic of the patient, in which succession: (1) during the follicular phase of the menstrual cycle there is: (a) a first period of absence of administration of any pharmacologically active steroid composition; and (b) a following period of administration of a low dose of one pharmacologically active steroid composition adapted to the identified endogenous estrogen characteristic of the patient and selected from the group of estrogenic active steroids and progestational active steroids; and (2) during the luteal phase of the menstrual cycle, there is administered an effective dosage of a pharmacologically active composition which comprises a combination of an estrogenic active steroid and a progestational active steroid; whereby a follicular and luteal phase correspondence is established between the pharmacological activity characteristics of the compositions administered and the menstrual cycle of the patient.
Claim 2
Dependent Claim
218 words
A treatment method for regulating the menstrual cycle of a presenting patient, the menstrual cycle having a first occurring follicular phase followed by a luteal phase, and the patient having a presenting endogenous estrogen characteristic, comprising: (A) determining the presenting endogenous estrogen characteristic of the patient and identifying the patient's presenting endogenous estrogen characteristic as one of (1) euestrogenic, (2) hyperestrogenic, (3) hypoestrogenic; (B) administering to the patient effective dosages of pharmacologically active steroid compositions in an ordered temporal succession based on the identified endogenous estrogen characteristic of the patient, in which succession: (1) during the follicular phase of the menstrual cycle there is: (a) a first period of absence of administration of any pharmacologically active steroid composition; and (b) a following period of administration of a low dose of one pharmacologically active steroid composition adapted to the identified endogenous estrogen characteristic of the patient and selected from the group of estrogenic active steroids and progestational active steroids; and (2) during the luteal phase of the menstrual cycle, there is administered an effective dosage of a pharmacologically active composition which comprises a combination of an estrogenic active steroid and a progestational active steroid; whereby a follicular and luteal phase correspondence is established between the pharmacological activity characteristics of the compositions administered and the menstrual cycle of the patient.
Claim 3
Dependent Claim
117 words
The method of claim 1 in which: (a) the presenting endogenous estrogen characteristics of the patient is identified as one of (1) euestrogenic and (2) hyperestrogenic; (b) pharmacologically active steroid compositions are administered for from 21 to 25 days in an ordered temporal succession during an approximately 28 day menstrual cycle; and (c) the follicular phase is approximately 14 to 15 days, during which: (i) no composition having a steroid activity is administered for a first approximately 3 to 7 day period; and (ii) a dosage of a progestational active steroid composition, equivalent in daily pharmacological activity to about 0.35 mgm. norethindrone by oral dosage, is administered for a following period of approximately 6 to 12 days.
Claim 4
Dependent Claim
61 words
The method of claim 2 in which pharmacologically active steroid compositions are administered for approximately 21 days, and the follicular phase is approximately 14 days during which: (i) no composition having a steroid activity is administered for a first approximately 7 day period; and (ii) the dosage of the progestational active steroid composition is administered for the following approximately 7 days.
Claim 5
Dependent Claim
102 words
The method of claim 1 in which: (a) the presenting endogenous estrogen characteristic of the patient is hypoestrogenic; (b) pharmacologically active steroid compositions are administered for approximately 21 days in an ordered temporal succession during an approximately 28 day menstrual cycle; and (c) the follicular phase is approximately 14 days, during which: (i) no composition having a steroid activity is administered for a first approximately 7 day period; and (ii) a dosage of an estrogenic active steroid composition, equivalent in daily pharmacological activity to about 0.02 mgm. ethinyl estradiol by oral dosage, is administered for a following period of approximately 7 days.
Claim 6
Dependent Claim
122 words
The method of claim 3 or claim 4 in which during the luteal phase the dosage of combined estrogenic active steroid and a progestational active steroid comprises: (i) an initially low dosage equivalent in daily pharmacological activity to about 0.02 mgm. ethinyl estradiol combined with about 0.35 mgm. norethindrone by oral dosage, for each day for the approximately first 7 days of the luteal phase; followed by (ii) a dosage of greater estrogenic and progestational activity than the initial dosage, said greater dosage being daily equivalent to about 0.035 mgm. to about 0.05 mgm. ethinyl estradiol combined with about 0.5 mgm. to about 1.0 mgm. norethindrone by oral dosage, for each day for the approximately last 7 days of the luteal phase.
Claim 7
Dependent Claim
158 words
The method of claim 3 or claim 4 in which during the luteal phase the dosage of a combined estrogenic active steroid and progestational active steroid comprises: (i) an initially low dosage equivalent in daily pharmacological activity to about 0.02 mgm. ethinyl estradiol combined with about 0.35 mgm. norethindrone by oral dosage for each day of the early stage of the luteal phase; followed by (ii) a dosage of greater estrogenic and progestational pharmacological activity than the initial dosage, said dosage being equivalent in daily pharmacological activity to about 0.05 mgm. ethinyl estradiol combined with about 1.0 mgm. to about 2.5 mgm. norethindrone by oral dosage, for each day of the intermediate stage of the luteal phase; followed by (iii) a dosage during the terminal stage of the luteal phase having a level of estrogenic and progestational pharmacological activity reduced by at least one-half daily from the level of pharmacological activity of the dosage during the intermediate stage.
Claim 8
Dependent Claim
42 words
The method of claim 6 in which the daily dosage for each day of the terminal stage of the luteal phase is equivalent in daily pharmacological activity to about 0.02 mgm. ethinyl estradiol combined with about 0.35 mgm. norethindrone by oral dosage.
Claim 9
Dependent Claim
76 words
The method of claim 6 in which: (i) the initial low dosage is administered each day for approximately 4 days; (ii) the dosage during the intermediate stage is administered for approximately 7 days and is equivalent in daily pharmacological activity to about 0.05 mgm. ethinyl estradiol combined with about 1.0 mgm. norethindrone by oral dosage; and (iii) the dosage during the terminal stage having a reduced level of pharmacological activity is administered for approximately 3 days.
Claim 10
Dependent Claim
76 words
The method of claim 6 in which: (i) the initial low dosage is administered each day for approximately 2 days; (ii) the dosage during the intermediate stage is administered for approximately 10 days and is equivalent in daily pharmacological activity to about 0.05 mgm. ethinyl estradiol combined with about 2.5 mgm. norethindrone by oral dosage; and (iii) the dosage during the terminal stage having a reduced level of pharmacological activity is administered for approximately 2 days.